SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-21-000054
Filing Date
2021-05-05
Accepted
2021-05-05 08:31:22
Documents
64
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20210331.htm   iXBRL 10-Q 1706793
2 EX-10.1 ex101amendandrestoutsidedi.htm EX-10.1 49051
3 EX-31.1 exhibit311q12021.htm EX-31.1 9978
4 EX-31.2 exhibit312q12021.htm EX-31.2 9976
5 EX-32.1 exhibit321q12021.htm EX-32.1 5680
6 EX-32.2 exhibit322q12021.htm EX-32.2 5787
  Complete submission text file 0001714899-21-000054.txt   6963744

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20210331.xsd EX-101.SCH 51079
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20210331_cal.xml EX-101.CAL 69137
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20210331_def.xml EX-101.DEF 246430
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20210331_lab.xml EX-101.LAB 589769
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20210331_pre.xml EX-101.PRE 383609
12 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20210331_htm.xml XML 1057454
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 21891301
SIC: 2836 Biological Products, (No Diagnostic Substances)